Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
Trial Details
- NCT ID
- NCT05552755
- Phase
- PHASE1 / PHASE2
- Sponsor
- Recursion Pharmaceuticals Inc.
- Status
- RECRUITING
- Cancer Type
- Colorectal Cancer
- Interventions
- Locations (sample)
- Scottsdale, Arizona, United States|33.50921,-111.89903
- Tucson, Arizona, United States|32.22174,-110.92648
- San Diego, California, United States|32.71571,-117.16472
- Naples, Florida, United States|26.14234,-81.79596
- Orlando, Florida, United States|28.53834,-81.37924
Key Eligibility Criteria
- Male or female and ≥ 18 years of age
- Have provided written informed consent to participate in the study
- Diagnosis of phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.
- Genetic diagnosis of FAP with APC gene mutation (Part 2 only).
For full eligibility, visit ClinicalTrials.gov.